Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia

Michael E. O'Dwyer, Brian J. Druker

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


The bcr-abl fusion protein is present in the vast majority of cases of chronic myelogenous leukemia, and the deregulated tyrosine kinase activity of this protein is essential for leukemic transformation. Thus, bcr-abl is an ideal target for pharmacologic inhibition. In preclinical studies, STI571 (formerly CGP57148B), an abl-specific, tyrosine kinase inhibitor, selectively killed bcr-abl-expressing cells both in vitro and in vivo. In early clinical trials of STI571, encouraging results have been obtained, and there is already a suggestion that STI571 may soon need to be incorporated into treatment algorithms for chronic myelogenous leukemia.

Original languageEnglish (US)
Pages (from-to)594-597
Number of pages4
JournalCurrent Opinion in Oncology
Issue number6
StatePublished - 2000

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia'. Together they form a unique fingerprint.

Cite this